Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy.
| Website: | www.nanoviricides.com |
| Email: | info@nanoviricides.com |
| Main Phone: | +1 203 937-6137 |
| Address: | 1 Controls Drive |
| State: | CT |
| City / Town: | Shelton |
| Country: | USA |
| Postal Code: | 6484 |
| Exchange: | AMX |
| CEO: | Irach Taraporewala |
| Employees: | 30 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 0.33 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid 0.33 | Bid Size 800.00 | Ask 0.34 | Ask Size 200.00 |
| Open 0.35 | High 0.35 | Low 0.33 | Prev Close 0.33 |
| Last Trade | Volume 59,543 | 52 Wk Hi 1.08 | 52 Wk Low 0.25 |
| Market Cap 22.9 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 69,383,000.00 | EPS (TTM) -0.12 | PE Ratio N/A | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 0 |
| Number of Buys | 0 | 0 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 0 |
| Last 10 Buys | Shares |
|---|---|
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Milton Boniuk | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Anil Diwan | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 7.21 | 7.21 | 7.21 | 7.21 |
| Low Target Price Estimate | 7.21 | 7.21 | 7.21 | 7.21 |
| Mean Target Price Estimate | 7.21 | 7.21 | 7.21 | 7.21 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 09/16/14 | 09/16/14 | 09/16/14 | 09/16/14 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 10-Q | Quarterly report with a continuing view of a company's financial position | 55 | 2018-05-21 |
| NT 10-Q | Notification that form 10-Q will be submitted late | 2 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-04 |
| 8-K | Report of unscheduled material events or corporate changes. | 24 | 2018-05-04 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 48 | 2018-02-20 |
| NT 10-Q | Notification that form 10-Q will be submitted late | 2 | 2018-02-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2017-12-15 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 29 | 2017-11-22 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 50 | 2017-11-14 |
| DEFR14A | Information for Proxy Statement under Rule 14a-101 | 35 | 2017-11-08 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 1 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
